Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, is supported by FDA Orphan Drug and Fast Track designations. Genprex highlighted the poor prognosis of ES-SCLC and the benefits of current treatments, emphasizing the potential of their therapy. Positive outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer have enabled an accelerated timeline for Acclaim-3.
Genprex, a clinical-stage gene therapy company, announced the appointment of Jose A. Moreno Toscano as Chairman of the Board following the passing of the previous Chairman, Rodney Varner. Mr. Moreno Toscano brings over 20 years of experience in the pharmaceutical and biotechnology industries, focusing on revenue growth, market expansion, and organizational development.
Genprex, a clinical-stage gene therapy company, announced the passing of its co-founder and CEO, Rodney Varner, due to complications from cancer. Ryan Confer has been appointed as the new President and CEO. Under Varner's leadership, the company achieved significant milestones in developing therapies for cancer and diabetes. The company expresses its condolences to Varner's family and colleagues.
Genprex, Inc. (
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
